INSM - Comprehensive Filing Intelligence

FY 2025•10-K•Filed Feb 19, 2026

5.0/10

Filing Health:CAUTION

Notable concerns that warrant closer review

Executive Summary

Gross margins are improving due to a more favorable product mix with the introduction of BRINSUPRI.. The company continues to operate at a net loss and negative operating cash flow, relying heavily on financing activities to fund operations.. Management does not expect litigation costs to materially impact financial position, results of operations, or cash flows.. Significant revenue growth of 66.7% driven by new product launch and existing product growth.

Top Concerns

!Aggressive capitalization of R&D related intangibles.
!High and increasing stock-based compensation relative to revenue.
!Management does not expect litigation costs to materially impact financial position, results of operations, or cash flows.
!Regulatory Compliance and Product Approval (high)
!Financial Viability and Capital Needs (high)

Top Positives

+Revenue has accelerated significantly due to the launch of BRINSUPRI and continued growth of ARIKAYCE, particularly internationally.
+Significant increases in R&D and SG&A expenses reflect ongoing investment in pipeline development and commercialization efforts for BRINSUPRI.

Analysis Dimensions

Our 5-pass AI analysis examines this filing across multiple dimensions. Each dimension score is derived from direct analysis of SEC filing text.

Narrative Intelligence

6.0/10

Management tone is balanced with focus on cost of product revenues as a percentage of revenues decreased due to sales of brinsupri, which has lower manufacturing costs than arikayce..

Full analysis includes: tone changes vs prior quarter, margin driver breakdown, forward guidance analysis, strategic priorities.

Accounting Quality

4.0/10

Earnings quality shows aggressive accounting practices.

Full analysis includes: reserve and allowance changes, non-recurring item analysis, stock-based compensation impact, disclosure concerns.

Hidden Liabilities

Off-balance sheet risk is low with $63.0 million in identified exposure.

Full analysis includes: cloud and purchase commitments, VIE/SPE exposure, covenant compliance status, refinancing risk assessment.

Risk Landscape

3.0/10

Overall risk profile shows regulatory compliance and product approval as primary concern.

Full analysis includes: 8 risk categories with severity, new vs escalated risks, management response assessment, risk trend analysis.

Segment Performance

7.0/10

Segment health analysis.

Full analysis includes: segment-by-segment revenue breakdown, geographic concentration risk, customer concentration analysis, segment margin trends.